Our results indicate that the POLQ H-score obtained from immunohistochemistry is a valuable prognostic biomarker for pancreatic cancer outcomes, which may also contribute to the future design of more personalized therapies that improve patient prognoses. This evidence concerns the gene POLQ and familial pancreatic carcinoma.